Article Listing - Uptake of Peg-IFN agents for HCV in China and South Korea hindered by relatively high cost and their partial reimbursement status

NEW DIAGNOSTIC FOR COLON CANCER

13 April 1992

Researchers at Johns Hopkins University Oncology Center claim to have developed the first diagnostic test capable of detecting the gene...

SUSPENSION OF DPT VACCINE

13 April 1992

Following the decision by the Department of Health in the Republic of China for an immediate temporary suspension of the...

FORTHCOMING MEETINGS

13 April 1992

Pharmaceutical industry meetings to be held in London by Management Forum shortly include:

- Improving Drug Development: Principles and Practice of...

"ROLLING" NDA FOR ADRIA'S RIFABUTIN

13 April 1992

A New Drug Application for Adria Laboratories' rifabutin, a product under development as a treatment for opportunistic Mycobacterium avium complex...

UPJOHN UPDATES ON R&D PROGRESS

13 April 1992

As the 1990s progress, US pharmaceutical company Upjohn faces a situation where several of its high-earning products will come to...

IMPROVED METERED DOSE INHALER

13 April 1992

Armstrong Pharmaceuticals has signed an exclusive license agreement option for an improved metered dose inhaler from Texax-Glynn Corp. The device...

ZOVIRAX AND SHINGLES

13 April 1992

Wellcome's Zovirax (aciclovir) should only be used to treat shingles if patients are immunocompromised, according to the UK Medicines...

CONTINENTAL CLOSES BIOLOGICALS DIVISION SALE

13 April 1992

Continental Pharma Cryosan Inc reports that it has received a cash payment of $16.9 million on closing the sale of...

HOECHST JAPAN MERGERS?

13 April 1992

Hoechst Japan Ltd has proposed that in order to strengthen its operation in the next five years it will examine...

NOVO-NORDISK'S rec INSULIN LAUNCHED IN FRANCE

13 April 1992

Novo-Nordisk has launched four formulations of its recombinant human insulin under the trade name Mixtard HMge Penfill. All the formulations...

Showing 94331-94340 of 95329 articles

Go to beginningPreviousNextGo to end